Salmeterol compared with current therapies in chronic asthma

Journal of Family Practice

Volumn 47, Issue 4, 1998, Pages 278-284

  Adinoff, Allen D ^a   Schwartz, Howard J ^b   Rickard, Kathleen A ^d   Yancey, Steven W ^c   Swearingen, Blake E ^c  

^a Respiratory Institute   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NONE

Author keywords

Adrenergic B agonist; Asthma; Bronchodilator; Salmeterol non MeSH

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LONG ACTING DRUG; NEDOCROMIL SODIUM; PLACEBO; SALBUTAMOL; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADOLESCENT; ADULT; AGED; AROUSAL; ARTICLE; ASTHMA; BRONCHODILATATION; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; NIGHT SLEEP; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SYMPTOMATOLOGY; TREMOR; WEANING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS;

EID: 0031722584     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sly RM. Mortality from asthma, 1979-1984. J Allergy Clin Immunol 1988; 82:705-17.
2. Weiss KB, Wagener DK. Changing patterns of asthma mortality. Identifying target populations at high risk. JAMA 1990; 264:1633-7.
3. Gergen DJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA 1990; 264:1688-92.
4. International consensus report on diagnosis and management of asthma. Bethesda, Md: National Heart, Lung, and Blood Institute, 1992. US Department of Health and Human Services publication No. 92-3091.
5. Expert Panel on the Management of Asthma. Guidelines for the diagnosis and management of asthma: executive summary. Bethesda Md: National Asthma Education Program, Office of Prevention, Education, and Control; National Heart, Lung, and Blood Institute, 1991. National Institutes of Health publication No. 91-3042.
6. British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign. Guidelines for the management of asthma in adults: I-chronic, persistent asthma. BMJ 1990; 301:651-3.
7. British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign. Guidelines for the management of asthma in adults: II-acute severe asthma BMJ 1990; 301:797-800.
8. Levison H. Canadian consensus on the treatment of asthma in children. Can Med Assoc J 1991; 145:1449-55.
9. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma N Engl J Med 1992; 327:1420-5.
10. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5:1062-87.
11. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271:1412-6.
12. Nathan RA, Seltzer JM, Kemp JP, Chervinsky P, Alexander WJ, Liddle R, Mills R. Safety of salmeterol in the maintenance treatment of asthma Ann Allergy Asthma Immunol 1995; 75:243-8.
13. Bousquet J, Aubert B, Bons J. Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma. Ann Allergy Asthma Immunol 1996; 76:189-94.
14. 2-agonist. BMJ 1990;301:1365-8.
15. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma Am Rev Respir Dis 1987; 136:225-44.
16. Gardner RM. Standardization of spirometry: a summary of recommendations from the American Thoracic Society. The 1987 update. Ann Intern Med 1988; 108:217-20.
17. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1958; 37(Pt 3):351-61.
18. Lundbäck B. A 3 months comparison of salmeterol and albuterol dry powder in mild to moderate asthmatic patients [abstract]. Am Rev Respir Dis 1991; 143:A651.
19. Fjellbirkeland L, Gulsvik A, Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 1994; 88:599-607.
20. Brambilla C, Chastang C, Georges D, Bertin L. Salmeterol compared with slow-release terbutaline in nocturnal asthma. Allergy 1994; 49:421-6.
21. Greening AP, Ind PW, Northfield M, Shaw G, on behalf of Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-24.
22. Lundbäck B, Rawlinson DW, Palmer JB. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48:148-53.
23. Charpin D, Vervloet D, Bons J, and a French Multicentre Study Group. Quality of life in moderate chronic asthma: salmeterol versus current treatments [abstract]. J Allergy Clin Immunol 1992; 89(1 Pt 2):189.
24. Highlights of the expert panel report 2: Guidelines for the diagnosis and management of asthma Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute, 1997. NIH publication No. 97-4051A.